Novartis enters agreement to acquire Mariana Oncology, …

Basel, May 2, 2024 – Novartis today announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, …

CouponFollow Extension

$1.75
OFF

Novartis Acquires Mariana In $1.75bn Deal To Strengthen ... - MSN

21 hours ago

Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from …

msn.com

$1.75
OFF

Novartis To Acquire Radiopharmaceutical Firm Mariana Oncology …

21 hours ago

May 3, 2024 · Novartis on Thursday announced plans to acquire radiopharmaceutical firm Mariana Oncology for up to $1.75 billion. The Swiss drugmaker said the deal will bolster its …

radiologybusiness.com

$1
OFF

Novartis Agrees To Acquire Mariana Oncology For $1 Billion, Gains …

21 hours ago

May 3, 2024 · “This acquisition brings to Novartis phenomenal talent and new capabilities in RLT research that complement our wide-ranging internal efforts to explore novel isotopes, …

biopharminternational.com

$1.75
OFF

Novartis To Buy Mariana Oncology For Up To $1.75 Billion In Boost …

21 hours ago

May 2, 2024 · Novartis agreed to acquire U.S. biotechnology company Mariana Oncology for up to $1.75 billion, in a deal that bolsters its radioligand therapy pipeline and efforts to develop …

morningstar.com

$1
OFF

Novartis Extends Its Reach In Radiopharmaceuticals With $1B …

21 hours ago

May 2, 2024 · Novartis is adding on to its capabilities in radiopharmaceuticals through a deal to acquire Mariana Oncology, a startup with a drug pipeline and technologies that diversify the …

medcitynews.com

$1.75
OFF

Novartis To Acquire Mariana For Up To $1.75B, Expanding …

21 hours ago

May 2, 2024 · Novartis has agreed to acquire Mariana Oncology for up to $1.75 billion, the companies said today, in a deal that would further expand the buyer’s radiopharmaceutical …

genengnews.com

$1
OFF

Novartis To Buy Mariana Oncology, Paying $1 Billion Upfront

21 hours ago

May 2, 2024 · Novartis agreed to buy US biotech Mariana Oncology Inc. to strengthen its pipeline of drugs that can specifically target cancer cells. The Swiss company said Bloomberg Terminal

bloomberg.com

$1.75
OFF

Novartis Acquires Mariana In $1.75bn Deal To Strengthen …

21 hours ago

May 4, 2024 · Novartis is firming its role as the top player in the radiopharmaceutical space with the acquisition of Mariana Oncology for $1bn upfront, and up to $750m in additional milestone …

borderless.net

$1
OFF

Novartis Entrenches Into Radiopharma With $1B Mariana Buy

21 hours ago

May 2, 2024 · With Novartis’ existing radioligand pipeline featuring Pluvicto and Lutathera and the Big Pharma model of taking drugs to market, Mariana CEO Simon Read, Ph.D., said the deal …

fiercebiotech.com

$1
OFF

Novartis To Buy Mariana Oncology For $1B Upfront (NYSE:NVS)

21 hours ago

Novartis (NYSE:NVS) has agreed to acquire cancer drugmaker Mariana Oncology for an upfront payment of $1B and an additional $750M in milestone payments.The transaction, subject to …

seekingalpha.com

$1
OFF

Novartis To Buy Mariana Oncology, Paying $1 Billion Upfront (1)

21 hours ago

May 2, 2024 · Novartis agreed to buy US biotech Mariana Oncology Inc. to strengthen its pipeline of drugs that can specifically target cancer cells.. The Swiss company said Thursday it will pay …

bloomberglaw.com

FAQs about Novartis enters agreement to acquire Mariana Oncology, … Coupon?

Does Novartis own Mariana oncology?

Basel, May 2, 2024 – Novartis today announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts focused on developing novel radioligand therapies (RLTs) to treat cancers with high unmet patient need. ...

How much will Novartis pay Mariana shareholders?

According to the deal terms announced Thursday, Novartis is paying $1 billion up front. Milestone payments could bring the Mariana shareholders another $750 million. Novartis is already a leader in radiopharmaceuticals with two commercialized therapies, Lutathera for gastroenteropancreatic neuroendocrine tumors and Pluvicto for prostate cancer. ...

What's the difference between Novartis and Mariana?

Novartis’ Pluvicto and Lutathera are approved for prostate cancer and neuroendocrine tumors, respectively, while Mariana’s pipeline tackles a wider range of tumor types and targets. While peers like Lilly have been focused on bulking up the manufacturing side of the business, Novartis’ interest in Mariana was more around innovation. ...

Should a biotech choose Novartis or Mariana?

While Mariana had a neatly planned pipeline, Read said a biotech always has to pick and choose the programs carefully based on financing, head count and other factors. With the weight of Novartis, the biotech can take a broader range of ideas forward and ultimately reach more patients than it ever could have alone. ...

What is Mariana & Novartis' strategy for end-to-end radiopharmaceutical R&D?

“Our strategy has centered on overcoming the unique challenges of end-to-end radiopharmaceutical R&D and ultimately, delivery of these drugs to the bedside,” Simon Read, PhD, Mariana’s founder and CEO, said in a statement. “Both Mariana and Novartis are committed to transforming cancer care, and together we will be in a better position to do that.” ...

Why did Novartis buy RLT?

The transaction bolsters the Novartis RLT pipeline and expands the company’s research infrastructure and clinical supply capabilities, supporting Novartis strategic priorities in oncology and RLT platform innovation. ...